GIP and metabolic dysfunction-associated steatohepatitis: The included studies were RCTs of adults with biopsy-confirmed, non-cirrhotic MASH (F2-F3) treated with resmetirom, GLP-1 receptor agonists, or GIP/GLP-1 receptor agonists, while non-randomized studies and pediatric and cirrhotic populations were excluded.